mazindol has been researched along with ADDH in 3 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mazindol CR was efficacious in the treatment of adults with ADHD, with a large effect size, and was well tolerated, supporting the progression to phase III." | 2.87 | A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). ( Handal, N; Konofal, E; Mulligan, I; Newcorn, JH; Schmith, V; Wigal, SB; Wigal, TL, 2018) |
| "Mazindol has been proposed as a potential treatment of children with attention deficit/hyperactivity disorder (ADHD)." | 2.79 | Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. ( Benadjaoud, L; Jacqz-Aigrain, E; Kaguelidou, F; Konofal, E; Laouénan, C; Lecendreux, M; Mentré, F; Zhao, W, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wigal, TL | 1 |
| Newcorn, JH | 1 |
| Handal, N | 1 |
| Wigal, SB | 1 |
| Mulligan, I | 1 |
| Schmith, V | 1 |
| Konofal, E | 2 |
| Zhao, W | 1 |
| Laouénan, C | 1 |
| Lecendreux, M | 1 |
| Kaguelidou, F | 1 |
| Benadjaoud, L | 1 |
| Mentré, F | 1 |
| Jacqz-Aigrain, E | 1 |
| Turle-Lorenzo, N | 1 |
| Maurin, B | 1 |
| Puma, C | 1 |
| Chezaubernard, C | 1 |
| Morain, P | 1 |
| Baunez, C | 1 |
| Nieoullon, A | 1 |
| Amalric, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)[NCT02808104] | Phase 2 | 84 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for mazindol and ADDH
| Article | Year |
|---|---|
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2018 |
Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Drug Administration Schedule; Fema | 2014 |
1 other study available for mazindol and ADDH
| Article | Year |
|---|---|
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention Deficit Disorder with Hyperactivity; Cognition; Corpus Stri | 2006 |